Meningococcal Disease: Recommended vaccinations
  General recommendation
  Recommendation for specific groups only
  Catch-up (e.g. if previous doses missed)
 
Vaccination not funded by the National Health system
 
Mandatory vaccination
MonthsYears
2345681112131415162321011121314151617181924≥ 25
Austria
MenB1
MenB1
MenB1
MenB
Men C - Men B
Men C - Men B
MCV4
MCV4/MenB
Belgium
MCV4
MCV4
Bulgaria
Croatia
Cyprus
MenC
MPSV42
Czech Republic
MenB3
MCV43
MCV4/MenB3
Denmark
Estonia
Finland
France
MenC
MenC
MenC4
Germany
MenC
MenC
Greece
MCV4/MenB
MenC
MenC
MCV4
MCV4
MCV4/MenB
Hungary
Iceland
MenC
MenC
Ireland
MenB
MenB
MenC
MenB
MenC5
MCV4
Italy
MenB6
MenB6
MenB6
MenB6
MenC7
MCV47
Latvia
Liechtenstein
MenC8
MenC9
Lithuania
MenB
MenB
MenB10
Luxembourg
MenB11
MenC
MenB11
MenC12
MenB11
Malta
MenB
MCV4
MenB
MCV4
MenB
MCV4
Netherlands
MCV413
MCV414
Norway
Poland
MenC
MenC
Portugal
MenB
MenB
MenB - MenC
Romania
Slovakia
Slovenia
Spain
MenC15
MenC15
MCV416
MCV417
Sweden

Footnotes:

  1. Please refer to official recommendations for timing and number of doses required according to age. For infants, 3 doses from 3 months of age with at least one month interval - Booster between 13-15 months.
  2. vaccines only given on specific indications
  3. 1. Vaccination with MenB vaccine and MCV4 vaccine is covered by health insurance for persons of all ages with immune disorders since January 2018. 2. Vaccination is covered by health insurance for small infants since May 2020 for MenB vaccine if vaccination is started before the age of six months and for MCV4 vaccine if vaccination is given as a single dose in the second year of life. 3. In September 2021, the inclusion of vaccinations with MCV4 and MenB vaccine for adolescents in addition to small infants as covered by health insurance was newly approved; from January 2022, an amendment to the law is to enter into force and vaccinations are to be paid for: a. MenB vaccine if it is started before the age of 12 months or from the completion of the fourteenth to the completion of the fifteenth year of the age; b. MCV4 vaccine if it is made in a single dose from the completion of the first to the completion of the second year of age or from the completion of the fourteenth to the completion of the fifteenth year of the age. Recommendation (Czech, English) http://www.szu.cz/ockovani-proti-meningokokovym-onemocnenim
  4. 1 dose until 24 years
  5. Hib/MenC combined vaccine
  6. Please refer to local recommendations for age of administration. MenB should not to be co-administered with other vaccinations.
  7. Meningococcal C vaccination, one dose for children between 13-15 months. Meningococcal ACWY, one dose for adolescents age 12-14
  8. not part of the basic vaccination plan. catch-up possible until 5 years of age
  9. not part of the basic vaccination plan. catch-up possible until 20 years of age
  10. Can be administered concomitantly with MMR
  11. Two/three doses recommended in at-risk groups, depending on age. Further information available at: http://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite/2018-avis-vaccination-meningocoque-groupe-b.pdf
  12. see http://sante.public.lu/fr/espace-professionnel/recommandations/conseil-maladies-infectieuses/meningite/2018-vaccination-meningocoque-c.pdf
  13. Replaced MenC in 2018.
  14. Introduced in 2018
  15. Additional information available at https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Preguntas_respuestas_Vacunacion_frente_meningitis.pdf
  16. One dose at 12 years to individuals who have not received any doses of MCV4 since 10 years of age. Additional information available at https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/Preguntas_respuestas_Vacunacion_frente_meningitis.pdf
  17. The catch-up vaccination programme for individuals aged 13 to 18 years will be introduced gradually (more information available at: http://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/enfmeningococica.htm)